Evaluating Disparities in Precision Oncology

BS

Bryan Schneider, MD

Principal Investigator

Status: Enrolling By Invitation Ages: 18 Years Gender: All Genders Phase: N/A 1 Locations

Brief Description

What is the purpose of this study?
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.

Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed Description

What will happen during the study?
  • This study proposes an innovative approach leveraging the molecular tumor boards across four comprehensive cancer centers, where real- world, diverse patients with metastatic cancer are seen receiving a broad scope of therapies in the context of precision medicine. 
  • The study plans to collect detailed clinical, social, and genomic data from patients to identify significant contributors of disparate survival and toxicity outcomes for patients with metastatic cancer.

Eligibility of study

Inclusion Criteria:
  1. Ability to provide written informed consent and HIPAA authorization
  2. Patients must be ≥ 18 years old at the time of consent
  3. Diagnosis of advanced or metastatic cancer and planning to undergo molecular testing as part of their routine cancer care
  4. Patients who self-report race as Black or patients who self-report as White
Exclusion Criteria:
N/A

Interested in participating?

Enrollment in IU School of Medicine clinical trials is managed through our All IN for Health program. Many studies only accept people who are part of an invited group. Visit allinforhealth.info to connect with the study team, or contact your doctor to see if you are eligible.